FIT Biotech Oy
Company release October 14, 2016 at 21.30 pm EET
Correction to company release: FIT Biotech Oy’s Board of Directors has decided on the issue of Convertible Notes and Warrants
FIT Biotech Oy’s company release published on October 14, 2016 at 17.45 EET contained an error related to the euro amount of the Convertible Notes with Warrants Funding Programme between the Company and Sitra. The correct euro amount is EUR 500,000.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
